Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present InVivo Therapeutics Holdings Corp (NASDAQ: NVIV).

Full DD Report for NVIV

You must become a subscriber to view this report.


Recent News from (NASDAQ: NVIV)

InVivo Therapeutics beats by $0.41
InVivo Therapeutics (NASDAQ: NVIV ): Q1 EPS of -$3.34 beats by $0.41 . Cash and cash equivalents of $11.6M Press Release More news on: InVivo Therapeutics Holdings Corp, Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: May, 07 2018 17:10
InVivo Therapeutics Reports 2018 First Quarter Financial Results
Progress Update on INSPIRE 2.0 Trial, Finance Officer Appointment InVivo Therapeutics Holdings Corp. (NVIV) today provided a business and clinical update and reported financial results for the quarter ended March 31, 2018. Richard Toselli, M.D., President and Chief Executive Off...
Source: Business Wire
Date: May, 07 2018 16:30
Your Daily Pharma Scoop: Achaogen Mixed Ad Com, Esperion Mixed Results, InVivo Up On Old Data
Analysis focus: AKAO So, the FDA Ad Com finally backed Achaogen’s (AKAO) plazomicin! While that is good that the committee voted 15-0 (1 abstain) in favor of the cUTI indication, it is not so good that they also voted 11-4 (1 abstain) that that the the data failed to provide subst...
Source: SeekingAlpha
Date: May, 04 2018 08:01
Midday Gainers / Losers (05/03/2018)
Gainers:  VVPR +179% . CLWT +71% . IMTE +55% . OTCQB:MKGI +40% . SEII +28% . AMRH +25% . STAA +26% . AMDA +22% . BOXL +20% . NDRA +18% . More news on: VivoPower International PLC, Euro Tech Holdings Company Limited, Integrated Media Technology Limited, ...
Source: SeekingAlpha
Date: May, 03 2018 12:40
Biotech Industry Presses Forward with Latest Transdermal Drug Delivery Advancements
Palm Beach, FL – (May 3, 2018) – The multi-billion dollar Biotech Industry is witnessing a transformation as it relates to the advancement of transdermal drug delivery patches. On the back of factors like rising number of transdermal drug delivery products, enhanced awareness in de...
Source: MarketNewsUpdates.com
Date: May, 03 2018 08:50
Midday Gainers / Losers (05/02/2018)
Gainers: IMTE +510% . NVIV +63% . WMLP +53% . HCHC +38% . NANO +27% . CYH +24% . FTR +23% . MTSI +18% . MBUU +18% . More news on: Integrated Media Technology Limited, InVivo Therapeutics Holdings Corp, Westmoreland Resource Partners, LP, Stocks on the move, , ...
Source: SeekingAlpha
Date: May, 02 2018 12:50
InVivo up 69% on previously reported INSPIRE results, equity offering looming
Thinly traded nano cap InVivo Therapeutics Holdings ( NVIV +68.7% ) is up on a whopping 68x surge in volume in apparent response to its announcement that six-month results from the Phase 3 INSPIRE study assessing its Neuro-Spinal Scaffold in spinal cord injury patients were presented at ...
Source: SeekingAlpha
Date: May, 02 2018 11:49
InVivo Therapeutics Announces Presentation of Complete Six-Month Primary Endpoint Results from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold(TM) in Acute Thoracic Complete Spinal Cord Injury
- Findings Presented at the 2018 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting - InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the presentation of the complete six-month primary endpoint results from the company’s single-ar...
Source: Business Wire
Date: May, 02 2018 08:00
Midday Gainers / Losers (04/27/2018)
Gainers : GNPX +36% . ENVA +27% . BOOM +24% . AQMS +20% . CYAD +19% . NVIV +17% . SIVB +16% . EHTH +16% . AQB +15% . KN +15% . More news on: Genprex, Inc, Enova International, Inc., DMC Global Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: April, 27 2018 12:45
Midday Gainers / Losers (04/25/2018)
Gainers:   TZOO   +25%.  VICR +24% . IPI +19% . CCRC +16% . EYPT +16% . BASI +15% . GNPX +12% . UAVS +14% . USNA +12% . STNG +12% . More news on: Travelzoo Inc, Vicor Corporation, Intrepid Potash, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: April, 25 2018 12:50

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-132.001.962.0031.92101,846
2018-08-102.001.982.001.94108,203
2018-08-092.001.9712.0041.96125,804
2018-08-082.091.982.091.97180,798
2018-08-071.972.0652.071.9580,609

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1342,50861,00469.6807Short
2018-08-1011,99242,57128.1694Cover
2018-08-0939,79472,78554.6734Short
2018-08-0819,08946,24641.2771Short
2018-08-0714,23727,83151.1552Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NVIV.


About InVivo Therapeutics Holdings Corp (NASDAQ: NVIV)

Logo for InVivo Therapeutics Holdings Corp (NASDAQ: NVIV)

InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in with proprietary technology co invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In the Company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA.

 

 

 

Current Management

  • Mark Perrin / CEO
  • Steven F. McAllister / CFO
  • Tamara Joseph / Senior VP, General Counsel
  • Thomas Ulich / CSO
  • Louis Vaickus / Chief Med. Officer
  • Brian Luque / Business Development, IR
  • Daniel R Marshak /

Current Share Structure

  • Market Cap: $23,060,746 - 03/21/2018
  • Issue and Outstanding: 38,054,036 - 03/09/2018

 


Recent Filings from (NASDAQ: NVIV)

Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: May, 17 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 07 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: May, 07 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 07 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: May, 07 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
General form for registration of securities under the Securities Act of 1933
Filing Type: S-1Filing Source: edgar
Filing Date: April, 24 2018
General form for registration of securities under the Securities Act of 1933
Filing Type: S-1Filing Source: edgar
Filing Date: April, 24 2018

 

 


Daily Technical Chart for (NASDAQ: NVIV)

Daily Technical Chart for (NASDAQ: NVIV)


Stay tuned for daily updates and more on (NASDAQ: NVIV)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: NVIV)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NVIV is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of NVIV and does not buy, sell, or trade any shares of NVIV. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/